HCW Biologics Inc. filed a Form 8-K on November 20, 2026, disclosing that its November 17, 2026 Special Meeting of Stockholders was adjourned without conducting any business due to insufficient quorum, and that a new Special Meeting has been scheduled for January 26, 2027.
Key Highlights
- Quorum not achieved: At the November 17, 2026 Special Meeting, shares present in person or by proxy were not sufficient to constitute a quorum, so no vote was taken.
- Proposal carried forward: The unvoted proposal concerns approval, under Nasdaq Listing Rule 5635(d), of share issuances upon exercise of warrants covering up to 618,682 shares at an exercise price of $2.585 per share.
- Warrants tied to July 2026 placement: The warrants were issued in connection with a private placement financing completed on July 29, 2026.
- New meeting set for January 26, 2027: The January 2027 Special Meeting will be held virtually at 10:00 A.M. Eastern Time, with a record date of December 15, 2026.
- Second proposal added: A new proposal covering warrants from a separate private placement that closed on September 23, 2026, also subject to Nasdaq Listing Rule 5635(d), will be added to the January 2027 meeting agenda.
- Proxy statement timeline: A preliminary proxy statement was filed November 18, 2026; the company expects to file the definitive proxy statement on or about December 17, 2026.
HCW Biologics Adjourns November Meeting, Sets January 2027 Vote on Warrant Issuances
According to the filing, HCW Biologics Inc. (NASDAQ:HCWB) convened a Special Meeting of Stockholders on November 17, 2026, but was unable to proceed because "there were not present in person or represented by proxy a sufficient number of shares of the Company's common stock to constitute a quorum." As a result, the meeting was adjourned without any business being conducted and no vote was taken.
The sole proposal before stockholders at that meeting sought approval, for purposes of Nasdaq Listing Rule 5635(d), of the issuance of shares upon exercise of common stock warrants exercisable for up to 618,682 shares at an exercise price of $2.585 per share. The filing states those warrants were issued pursuant to transaction documents entered into in connection with a private placement financing completed on July 29, 2026.
The company disclosed that a new Special Meeting has been scheduled for January 26, 2027, to be held virtually at 10:00 A.M. Eastern Time. The record date for that meeting is December 15, 2026. In addition to carrying over the original proposal, the January 2027 meeting will include a second proposal: approval of share issuances upon exercise of warrants from a separate private placement offering that closed on September 23, 2026, also as required by Nasdaq Listing Rule 5635(d). The company stated it intends to file a definitive proxy statement on or about December 17, 2026, and that it "intends to solicit proxies from its stockholders" before the January 2027 meeting. The filing was signed by Hing C. Wong, Founder and Chief Executive Officer.
What Was Disclosed
HCW Biologics reported that its November 17, 2026 Special Meeting adjourned without a quorum, deferring a warrant issuance approval vote to a new Special Meeting set for January 26, 2027, which will also include a second warrant issuance proposal from a September 2026 private placement.



Please wait processing your request...